Binimetinib Patent Expiration
Binimetinib is Used for treating melanoma and non-small cell lung cancer in combination with encorafenib for patients with a BRAF mutation. It was first introduced by Array Biopharma Inc
Binimetinib Patents
Given below is the list of patents protecting Binimetinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Mektovi | US9562016 | Preparation of and formulation comprising a MEK inhibitor | Oct 18, 2033 | Array Biopharma Inc |
| Mektovi | US9598376 | Preparation of and formulation comprising a MEK inhibitor | Oct 18, 2033 | Array Biopharma Inc |
| Mektovi | US9980944 | Preparation of and formulation comprising a MEK inhibitor | Oct 18, 2033 | Array Biopharma Inc |
| Mektovi | US9314464 | Compounds and compositions as protein kinase inhibitors | Jul 04, 2031 | Array Biopharma Inc |
| Mektovi | US10005761 | Compounds and compositions as protein kinase inhibitors | Aug 27, 2030 | Array Biopharma Inc |
| Mektovi | US9593100 | Compounds and compositions as protein kinase inhibitors | Aug 27, 2030 | Array Biopharma Inc |
| Mektovi | US9850229 | Compounds and compositions as protein kinase inhibitors | Aug 27, 2030 | Array Biopharma Inc |
| Mektovi | US7777050 | N3 alkylated benzimidazole derivatives as MEK inhibitors | Mar 13, 2027 | Array Biopharma Inc |
| Mektovi | US8178693 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar 13, 2023
(Expired) | Array Biopharma Inc |
| Mektovi | US8193229 | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar 13, 2023
(Expired) | Array Biopharma Inc |
| Mektovi | US8513293 | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal |
Mar 13, 2023
(Expired) | Array Biopharma Inc |
Binimetinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Binimetinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
